LB-S&T-29 SEMINAL CITRATE: A NEW MARKER FOR THE DETECTION OF PROSTATE CANCER?

Abstract

You have accessJournal of UrologyLate-Breaking S&T Poster1 Apr 2016LB-S&T-29 SEMINAL CITRATE: A NEW MARKER FOR THE DETECTION OF PROSTATE CANCER? EMERSON GREGÓRIO, ANTONIO ALEXANDRINO, IVANIA SCHUQUEL, WILLIAN COSTA, and MARCO AURÉLIO RODRIGUES EMERSON GREGÓRIOEMERSON GREGÓRIO More articles by this author , ANTONIO ALEXANDRINOANTONIO ALEXANDRINO More articles by this author , IVANIA SCHUQUELIVANIA SCHUQUEL More articles by this author , WILLIAN COSTAWILLIAN COSTA More articles by this author , and MARCO AURÉLIO RODRIGUESMARCO AURÉLIO RODRIGUES More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.03.110AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To establish whether the citrate concentration in the seminal fluid ([CITRATE]) measured by means of high-resolution nuclear magnetic resonance spectroscopy (1HNMRS) is superior to the serum prostate-specific antigen (PSA) concentration in detecting prostate cancer (PCa) in men with elevated PSA. METHODS The group of patients consisted of 32 consecutively seen men with histological diagnosis of clinically localized PCa. The control group consisted of 32 men under long-term follow-up (mean of 4.64 ± 2.88 years) for benign prostate hyperplasia, with elevated PSA (above 4 ng/ml) and several prostate biopsies negative for cancer (mean of 2.61 ± 1.38 biopsies per control). Samples of blood and seminal fluid (by masturbation) for measurement of PSA and [CITRATE], respectively, were collected from patients and controls; [CITRATE] was determined by means of 1HNMRS. The capacities of PSA and [CITRATE] to predict PCa were compared by means of univariate analysis and receiver operating characteristic (ROC) curves. RESULTS Median [CITRATE] was significantly lower among the patients with PCa compared to the controls (4.76 mM/l vs. 13.74 mM/l). There was no significant difference in the median PSA between patients and controls (7.94 ng/ml vs. 8.25 ng/ml). The accuracy of [CITRATE] for detecting PCa was significantly superior compared to PSA (73.1% vs. 53.4%). CONCLUSIONS Measurement of [CITRATE] by means of 1HNMRS is superior to PSA for early detection of PCa in men with elevated PSA. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e348 Advertisement Copyright & Permissions© 2016MetricsAuthor Information EMERSON GREGÓRIO More articles by this author ANTONIO ALEXANDRINO More articles by this author IVANIA SCHUQUEL More articles by this author WILLIAN COSTA More articles by this author MARCO AURÉLIO RODRIGUES More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...